Bridgefront Capital’s Mersana Therapeutics MRSN Stock Holding History

Bridgefront Capital’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-625	Closed	-$97K	–	373
2021 Q4	$97K	Buy	+625	New	+$122K	0.09%	272
2021 Q3	–	Sell	-449	Closed	-$153K	–	559
2021 Q2	$153K	Buy	+449	New	+$170K	0.06%	529

Other funds holding MRSN

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return